hotspot -WSS

hotspot

author：hotspot 2025-09-28 00:51:56 - browse：799

Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medical records are filled with copy
Next article： J&J to emphasize cancer drugs, stop much of its vaccine research

explore

leisure time

WSS

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

5 shark bites reported on Long Island as officials deploy surveillance drones

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Disappointing trial forces Pfizer to pivot on obesity medicine plans

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

2 million sign

Wikipedia

hotspot

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Pediatric cancer treatments threatened by a new FDA policy

Medical records are filled with copy

Condition critical? Britain's beloved but battered National Health Service turns 75

Walensky prepares to leave CDC — and Congress — behind

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

Apple is now the first public company to be valued at $3 trillion

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CDC director unscathed in first congressional testimony

focus

BIO selects John Crowley as new CEO

As biotech industry slumps, bioscience job market is upside down

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Following judge's order, DOJ releases slightly less

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Pediatric cancer treatments threatened by a new FDA policy

hotspot

explore

leisure time

entertainment